Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 3Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 1278Carcinoma, Non-Small-Cell Lung 926Prostatic Neoplasms 729Neoplasms 633Multiple Myeloma 554Lymphoma 540Colorectal Neoplasms 530Lung Neoplasms 515Leukemia 498Leukemia, Myeloid, Acute 473Neoplasm Metastasis 471Melanoma 426Lymphoma, Non-Hodgkin 420Ovarian Neoplasms 417Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 329Head and Neck Neoplasms 307Lymphoma, Large B-Cell, Diffuse 295Glioblastoma 294Myelodysplastic Syndromes 288Lymphoma, Follicular 287Brain Neoplasms 287Stomach Neoplasms 280Carcinoma, Renal Cell 268Carcinoma, Hepatocellular 262Hodgkin Disease 261Rectal Neoplasms 256Sarcoma 250

Interventions

pembrolizumab 24-fluorobenzoyl-TN-14003 2olaparib 1irinotecan sucrosofate 1Leucovorin 1Fluorouracil 1Drug Therapy 1BKT140 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × Metastatic Pancreatic Adenocarcinoma × Clear all
NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled 12 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02677038 2024-10-01

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 8 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02826486 2024-08-28

COMBAT

BioLineRx, Ltd.

Phase 2 Completed
80 enrolled 13 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡